Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer In Vitro and In Vivo.
Dreyer TF, Kuhn S, Stange C, Heithorst N, Schilling D, Jelsma J, Sievert W, Seitz S, Stangl S, Hapfelmeier A, Noske A, Wege AK, Weichert W, Ruland J, Schmitt M, Dorn J, Kiechle M, Reuning U, Magdolen V, Multhoff G, Bronger H. Dreyer TF, et al. Cancer Immunol Res. 2021 Jul;9(7):779-789. doi: 10.1158/2326-6066.CIR-20-0327. Epub 2021 Apr 27. Cancer Immunol Res. 2021. PMID: 33906866
Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells.
Lieber S, Reinartz S, Raifer H, Finkernagel F, Dreyer T, Bronger H, Jansen JM, Wagner U, Worzfeld T, Müller R, Huber M. Lieber S, et al. Oncoimmunology. 2018 Mar 15;7(5):e1424672. doi: 10.1080/2162402X.2018.1424672. eCollection 2018. Oncoimmunology. 2018. PMID: 29721385 Free PMC article.
miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.
Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Carcinogenesis. 2020 Jun 17;41(4):442-451. doi: 10.1093/carcin/bgz163. Carcinogenesis. 2020. PMID: 31586203
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Int J Cancer. 2020 Dec 15;147(12):3560-3573. doi: 10.1002/ijc.33182. Epub 2020 Aug 1. Int J Cancer. 2020. PMID: 32621752 Free article.
28 results